KRAS and adenocarcinoma: However, there is a significant decrease in KRAS G12V during adenoma to adenocarcinoma progression (see Fig. 1) [Parsons et al., 2010], and there is a significant inverse correlation between KRAS G12V MF and maximum tumor dimension for colon tumors and papillary thyroid carcinomas [Parsons and Myers, 2013], but not for lung adenocarcinomas [Myers et al., 2015].